Enteris BioPharma utilizes its Peptelligence® and ProPerma® platforms to build long-term relationships with clients that recognize the business value and patient advantages of orally delivered peptide and small molecule therapeutics.
Peptides and small molecules with poor oral absorption are commonly administered by painful injections, which can lower patient compliance and limit market opportunities for drugmakers. At Enteris, we strive to create innovative therapeutics to improve the lives of patients by developing proprietary, patent-protected oral formulations, which bring game-changing benefits compared to more invasive routes of administration. We partner with clients at various stages of development, from early drug discovery to late-stage clinical, as well as life cycle management of marketed products.
Oral Peptide #1
Small Molecule #1
Small Molecule #2